Researchers reveal prostate tumors 'fed' by fatty acids

February 06, 2019

An international multidisciplinary study initiated by Melbourne scientists has shown a link between prostate cancer and the uptake of fatty acids by cancer cells.

The findings point to a possible therapeutic target for this common cancer.

Prostate cancer is the second most diagnosed cancer in men, accounting for 15 per cent of male cancer diagnoses and 8 per cent of all cancer cases. More than 17 700 estimated new cases were diagnosed in 2018 in Australia.

Monash Biomedicine Discovery Institute (BDI) Deputy Director of Cancer Program Renea Taylor and University of Melbourne Physiology Department Head Matthew Watt co-led a research program investigating cancer metabolism, looking for fuel sources for particular cancers, and identified fatty acids as an important source for prostate tumours.

Associate Professor Taylor said: "There is a strong link between obesity, diet and poor outcomes in men who develop prostate cancer. In particular, those men who consume more saturated fatty acids seem to have more aggressive cancer."

The researchers found that fatty acids are taken up into prostate cancer cells and increase tumour growth. They then blocked the uptake of fatty acid by genetically deleting the key fatty acid transporter and showed that they could slow the cancer's development.

The key to the discovery was the combination of Professor Watt's world-class expertise as a metabolic researcher with Associate Professor Taylor's strong record as a cancer biologist and their use of human tissue samples of prostate cancer.

Professor Watt said: "We've known for many years that dysfunctional fatty acid metabolism is linked to many chronic diseases.

Applying this knowledge to cancer, and providing the evidence to develop a therapy to treat a disease that impacts so many men is deeply satisfying."

He said the major clinical challenge in the field was to prevent progression to aggressive disease.

Associate Professor Taylor said: "Our whole concept is about giving more appropriate treatment earlier to stop men getting to the late or advanced stage. Our studies showed that blocking fatty acid transport is one way to do this."
-end-
The research was funded by Prostate Cancer Foundation of Australia, the Diabetes Australia Research Trust and the Cancer Council Victoria.

About the University of Melbourne Department of Physiology

The Department of Physiology was established in 1862 and has a proud and strong record of excellence in research, research training, learning and teaching, community and media engagement. The Department's goal is to remain at the forefront of scientific research using novel and imaginative research methods to study cardiovascular health, neurophysiology, and muscle and exercise physiology.

About the Monash Biomedicine Discovery Institute

Committed to making the discoveries that will relieve the future burden of disease, the newly established Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.

University of Melbourne

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.